Drugs / Polydeoxyribonucleotide
Polydeoxyribonucleotide
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 43 trials | ||||||
| Phase 4 | NCT03916198 | May 2019 → Aug 2021 | rotator cuff syndrome | Chuncheon Sacred Heart Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03388255 | Nov 2016 → Oct 2019 | scleroderma | Mastelli S.r.l | Terminated | No outcome recorded |
| Phase 4 | NCT00638872 | Oct 2007 → Dec 2010 | ulcer of lower limbs | University of Messina | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05464654 | Jun → Nov 2021 | postmenopausal atrophic vaginitis | Hospital Regional 1o de Octubre | Completed | No outcome recorded |
| — | NCT06753630 | Nov 2014 → Nov 2015 | epicondylitis | Chuncheon Sacred Heart Hospital | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07472192 Comparator | Mar → Jul 2026 overdue | — | Misr University for Science and Technology | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Polydeoxyribonucleotide | “The aim of the study was to compare the efficacy of vaginal biorevitalization to improve the genitourinary syndrome of menopause (GSM) between the gold-standard treatment with...” NCT05464654 ↗ |
| Known as | PDRN | “The aim of the study was to compare the efficacy of vaginal biorevitalization to improve the genitourinary syndrome of menopause (GSM) between the gold-standard treatment with...” NCT05464654 ↗2“Additionally, they will receive a 3mL injection of polydeoxyribonucleotide (PDRN) at the first outpatient department visit.” NCT06753630 ↗ “Polydeoxyribonucleotide -Placentex Mastelli(Pdrn)” NCT00638872 ↗ |
| Known as | Placentex Mastelli | “Polydeoxyribonucleotide -Placentex Mastelli(Pdrn)” NCT00638872 ↗ |
| Action | Activate | “Polydeoxyribonucleotide activates the adenosine receptor subtype A2A, resulting in tissue growth and neogenesis.” PMID 29094396 ↗ Nov 2017 |
| Route | Intramuscular | “perilesional or intramuscular injections” NCT00638872 ↗ |